Senate Finance Committee Chair Ron Wyden is considering substituting domestic reference pricing for House Democrats’ international reference pricing scheme in his bill to let Medicare negotiate drug prices, and the Oregon Democrat is considering including a drug appraisal entity that would help government negotiators by assessing what drugs are worth, according to lobbyists who support government negotiation.